dulaglutide vs lixisenatide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
dulaglutide · Trulicity
Marketed by Eli Lilly
NCT01394952 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial involving 9,901 participants. The hard clinical primary endpoint was met: 594 dulaglutide participants versus 663 placebo participants experienced a composite cardiovascular event, with a hazard ratio of 0.88 (p=0.026).
Next expected readout: April 2027 · NCT07537088 (registry estimate)
Reported efficacy
Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Change in Hemoglobin A1c (HbA1c) From Baseline (Baseline, Week 36): Dulaglutide 1.5 mg -1.53 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 3 mg -1.71 Percentage of HbA1c (Standard Error 0.04) | Dulaglutide 4.5 mg -1.87 Percentage of HbA1c (Standard Error 0.04) (met)
Result source: NCT03495102
lixisenatide · Adlyxin / Lyxumia
Marketed by Sanofi and partners
NCT00707031 · Phase 3 · completed
The 639 participants were randomly assigned to lixisenatide or active treatment with exenatide, but the study was not blinded. The primary HbA1c comparison met its prespecified non-inferiority criterion, with a between-group difference of 0.17 percentage points and a 95% confidence interval of 0.033 to 0.297, but HbA1c is a surrogate endpoint rather than a hard clinical outcome.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
Reported efficacy
Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 (Baseline, Week 24): Lixisenatide -0.79 percentage of hemoglobin (Standard Error 0.053) vs Exenatide -0.96 percentage of hemoglobin (Standard Error 0.054) (met)
Result source: NCT00707031
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | dulaglutide | lixisenatide |
|---|---|---|
| HbA1c, change | -2.0% vs -1.1%−0.9 vs placeboNCT0459162625 other results
| -0.6% vs 0.1%−0.6 vs placeboNCT0179870619 other results
|
| Body weight, change (kg) | -0.8 vs 0.4−1.2 vs placeboNCT0459162618 other results
| -0.6 vs 1.0vs Insulin GlulisineNCT0176855917 other results
|
| HbA1c below 7% | 75.9% vs 33.8%+42.1 vs placeboNCT045916268 other results
| 53% vs 38.8%+14.2 vs placeboNCT0116977910 other results
|
| Fasting plasma glucose, change | -2.4 vs -2.6vs Insulin GlargineNCT016485823 other results
| -0.3 vs 0.0−0.3 vs placeboNCT0179870617 other results
|
| 3-point MACE (% with event) | 12% vs 13.4%−1.4 vs placeboNCT013949521 other result
| —Not reported |
HbA1c, change
- dulaglutide
- -2.0% vs -1.1%−0.9 vs placeboNCT04591626
25 other results
- -1.3% vs -0.5% NCT02597049
- -1.3% vs -0.5% NCT02597049
- -1.2% vs -0.5% NCT02597049
- -1.2% vs -0.5% NCT02597049
- -1.4% vs -0.7% NCT02152371
- -1.4% vs -0.1% NCT01769378
- -1.2% vs -1.1% NCT01621178
- -1.7% vs -1.2% NCT01648582
- -1.5% vs -0.9% NCT01644500
- -1.4% vs -1.4% NCT01624259
- -1.1% vs -1.1% NCT01621178
- -1.3% vs -1.2% NCT01648582
- -1.2% vs -0.9% NCT01644500
- -1.4% vs -0.9% NCT01584232
- -1% vs 0.5% NCT02963766
- -0.5% vs 0.5% NCT02963766
- -0.9% vs -1.7% NCT04255433
- -1.1% vs -1% NCT01621178
- -1.5% vs -0.9% NCT01648582
- -1.1% vs -1% NCT01621178
- -1.0% vs -0.9% NCT01648582
- -1.4% vs -0.4% NCT02973100
- -1.3% vs -0.4% NCT02973100
- -1.2% vs -0.4% NCT02973100
- -1.4% vs 0.1% NCT02750410
- lixisenatide
- -0.6% vs 0.1%−0.6 vs placeboNCT01798706
19 other results
- -0.8% vs -0.5% NCT01169779
- -0.7% vs -0.4% NCT00975286
- -0.9% vs -0.3% NCT00763815
- -0.7% vs -0.4% NCT00715624
- -0.8% vs -0.1% NCT00713830
- -0.8% vs -0.4% NCT00763451
- -0.9% vs -0.4% NCT00763451
- -0.8% vs 0.1% NCT00866658
- -0.6% vs -0.8% NCT01768559
- -0.8% vs -1.0% NCT00707031
- -1.9% vs -1.7% NCT05413369
- -1.1% vs -0.6% NCT02058160
- -1.6% vs -1.3% NCT02058147
- -0.8% vs -1.3% NCT02058147
- -1.9% vs -1.7% NCT05413369
- -0.7% vs -0.7% NCT00976937
- -1.8% vs -1.6% NCT01476475
- -0.6% vs -0.7% NCT01596504
- -0.3% vs -0.5% NCT01175473
Body weight, change (kg)
- dulaglutide
- -0.8 vs 0.4−1.2 vs placeboNCT04591626
18 other results
- -1.9 vs 0.5 NCT02152371
- -0.9 vs -0.2 NCT01769378
- -2.8 vs 1.1 NCT01621178
- -1.5 vs 1.0 NCT01648582
- -1.5 vs 0.9 NCT01644500
- -2.9 vs -3.6 NCT01624259
- -2.7 vs 1.6 NCT01621178
- -1.1 vs 1.4 NCT01648582
- -2.0 vs 1.1 NCT01621178
- -0.9 vs 1.0 NCT01648582
- -0.8 vs 0.9 NCT01644500
- -1.7 vs 1.6 NCT01621178
- -0.8 vs 1.4 NCT01648582
- -0.5 vs 0.9 NCT01584232
- -4.1 vs -1.6 NCT02973100
- -3.9 vs -1.6 NCT02973100
- -2.8 vs -1.6 NCT02973100
- -0.2 vs -0.3 NCT02750410
- lixisenatide
- -0.6 vs 1.0vs Insulin GlulisineNCT01768559
17 other results
- -1.5 vs -0.2 NCT01798706
- -1.5 vs -1.2 NCT01169779
- 0.3 vs 1.2 NCT00975286
- -0.2 vs 0.2 NCT00763815
- -1.8 vs -0.5 NCT00715624
- -1.8 vs -0.9 NCT00713830
- -2.7 vs -1.6 NCT00763451
- -2.6 vs -1.6 NCT00763451
- -0.4 vs 0.1 NCT00866658
- -3.0 vs -4.0 NCT00707031
- -0.3 vs 1.2 NCT05413369
- -0.7 vs 0.7 NCT02058160
- -0.3 vs 1.1 NCT02058147
- -2.5 vs -1.2 NCT00976937
- -2.3 vs 1.1 NCT02058147
- -1.0 vs 0.5 NCT01476475
- -1.6 vs -2.4 NCT01596504
HbA1c below 7%
- dulaglutide
- 75.9% vs 33.8%+42.1 vs placeboNCT04591626
8 other results
- 32.9% vs 29.1% NCT01621178
- 37.5% vs 34.6% NCT01621178
- 33.5% vs 29.1% NCT01621178
- 31.7% vs 34.6% NCT01621178
- 68.2% vs 20% NCT02973100
- 71.2% vs 20% NCT02973100
- 71.2% vs 20% NCT02973100
- 0% vs 47.4% NCT02750410
- lixisenatide
- 53% vs 38.8%+14.2 vs placeboNCT01169779
10 other results
- 56.3% vs 38.5% NCT00975286
- 52.3% vs 26.4% NCT00763815
- 28.3% vs 12% NCT00715624
- 36.4% vs 13.5% NCT00713830
- 42.1% vs 24.1% NCT00763451
- 47.4% vs 24.1% NCT00763451
- 35.6% vs 5.2% NCT00866658
- 48.5% vs 49.8% NCT00707031
- 72.5% vs 59.8% NCT05413369
- 40.7% vs 40% NCT00976937
Fasting plasma glucose, change
- dulaglutide
- -2.4 vs -2.6vs Insulin GlargineNCT01648582
3 other results
- -2.2 vs -2.4 NCT01648582
- -1.7 vs -2.6 NCT01648582
- -1.5 vs -2.4 NCT01648582
- lixisenatide
- -0.3 vs 0.0−0.3 vs placeboNCT01798706
17 other results
- -0.7 vs -0.2 NCT01169779
- 0.3 vs 0.5 NCT00975286
- -1.2 vs -0.3 NCT00763815
- -0.6 vs -0.6 NCT00715624
- -1.0 vs -0.4 NCT00713830
- -0.6 vs 0.1 NCT00763451
- -0.5 vs 0.1 NCT00763451
- -0.4 vs 0.3 NCT00866658
- -0.2 vs -0.2 NCT01768559
- -1.2 vs -1.4 NCT00707031
- -3.2 vs -3.5 NCT05413369
- -0.3 vs -0.5 NCT02058160
- -3.5 vs -3.3 NCT02058147
- -0.5 vs -0.7 NCT00976937
- -1.5 vs -3.3 NCT02058147
- -3.4 vs -3.5 NCT01476475
- 0.1 vs 0.1 NCT01596504
3-point MACE (% with event)
- dulaglutide
- 12% vs 13.4%−1.4 vs placeboNCT01394952
1 other result
- 13.1% vs 12.2% NCT04255433
- lixisenatide
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
12 other shared endpoints and safety
Coverage. dulaglutide: 16 of 16 rows · lixisenatide: 16 of 16 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | dulaglutide Rows use multiple source trials | lixisenatide Rows use multiple source trials |
|---|---|---|
| Daily Insulin Dose absolute change · per day | 20.05 vs 16.84 Insulin Glargine per day @ 52wk1.5 mga,b,c,d NCT01621178 · Phase 3 show 1 more dose27.46 vs 16.84 Insulin Glargine per day @ 52wk0.75 mg NCT01621178 · Phase 3 | -5.62 vs -1.93 placebo per day @ 24wkb,c,d NCT00715624 · Phase 3 · registry result, not featured evidence |
| Glycemic Rescue responder rate · % of participants | 2.1% (n=239) vs 11.7% (n=60) placebo @ 24wke,c NCT01769378 · Phase 3 · registry result, not featured evidence | 2.2% (n=315) vs 3.8% (n=315) Exenatide @ 24wke,c NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 13 other source trials5.2% (n=291) vs 6.9% (n=291) IDegAsp @ 24wk NCT05413369 · Phase 3 · registry result, not featured evidence 2.7% (n=366) vs 6% (n=365) Insulin Glargine NCT02058160 · Phase 3 · registry result, not featured evidence 2.9% (n=175) vs 10.4% (n=173) placebo @ 24wk NCT01798706 · Phase 3 · registry result, not featured evidence 3.6% (n=195) vs 6.7% (n=193) placebo @ 24wk NCT01169779 · Phase 3 · registry result, not featured evidence 0.4% (n=223) vs 0.4% (n=223) placebo @ 24wk NCT00975286 · Phase 3 · registry result, not featured evidence 3.8% (n=320) vs 11.3% (n=159) placebo @ 24wk NCT00763815 · Phase 3 · registry result, not featured evidence 9.5% (n=158) vs 6.8% (n=161) Sitagliptin @ 24wk NCT00976937 · Phase 3 · registry result, not featured evidence 5.8% (n=327) vs 7.2% (n=166) placebo @ 24wk NCT00715624 · Phase 3 · registry result, not featured evidence 4% (n=570) vs 12.6% (n=286) placebo @ 24wk NCT00713830 · Phase 3 · registry result, not featured evidence 1.3% (n=160) vs 4.4% (n=159) placebo @ 24wk NCT00763451 · Phase 3 · registry result, not featured evidence 3.1% (n=160) vs 4.4% (n=159) placebo @ 24wk NCT00763451 · Phase 3 · registry result, not featured evidence 1.3% (n=154) vs 3.2% (n=157) placebo @ 24wk NCT00866658 · Phase 3 · registry result, not featured evidence 0% (n=161) vs 0.6% (n=162) Insulin Glargine @ 24wk NCT01476475 · Phase 2 · registry result, not featured evidence |
| HbA1c absolute change · percentage points No placebo or comparator arm | -1.5% (n=383) @ 52wk1.5 mga,e,c,d NCT04809220 · Phase 3 · registry result, not featured evidence show 1 more dose-1.19% (n=193) @ 52wk0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence | -0.74% (n=222) @ 24wka,e,c,d NCT01517412 · Phase 3 · registry result, not featured evidence show 1 more dose-0.65% (n=218) @ 24wk NCT01517412 · Phase 3 · registry result, not featured evidence |
| HbA1c 6 5 or Less responder rate · % of participants HbA1c ≤6.5% | 59.4% (n=239) vs 41.3% (n=242) Glimepiride @ 26wk1.5 mga,e,c,f NCT01644500 · Phase 3 · registry result, not featured evidence show 1 more dose47.7% (n=239) vs 41.3% (n=242) Glimepiride @ 26wk0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence | 55.8% (n=468) vs 39.5% (n=466) Insulin Glargine @ 30wka,e,c,f NCT02058147 · Phase 3 · registry result, not featured evidence show 1 more dose19.3% (n=233) vs 39.5% (n=466) Insulin Glargine @ 30wk NCT02058147 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7 Without Hypoglycemia responder rate · % of participants | 74.8% (n=139) vs 33.3% (n=147) placebo @ 28wk1.5 mge,c,g NCT04591626 · Phase 3 · registry result, not featured evidence · add on | 31.7% (n=366) vs 18.6% (n=365) Insulin Glargine @ 30wke,c,g NCT02058160 · Phase 3 · registry result, not featured evidence 2 other source trials53.6% (n=468) vs 44.4% (n=466) Insulin Glargine @ 30wk NCT02058147 · Phase 3 · registry result, not featured evidence 30.5% (n=233) vs 44.4% (n=466) Insulin Glargine @ 30wk NCT02058147 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain responder rate · % of participants | 51.8% (n=139) vs 21.1% (n=147) placebo @ 28wk1.5 mge,c,g NCT04591626 · Phase 3 · registry result, not featured evidence · add on | 19.9% (n=366) vs 9% (n=365) Insulin Glargine @ 30wke,c,g NCT02058160 · Phase 3 · registry result, not featured evidence 2 other source trials31.8% (n=468) vs 18.9% (n=466) Insulin Glargine @ 30wk NCT02058147 · Phase 3 · registry result, not featured evidence 26.2% (n=233) vs 18.9% (n=466) Insulin Glargine @ 30wk NCT02058147 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7 Without Weight Gain responder rate · % of participants | 51.8% (n=139) vs 21.1% (n=147) placebo @ 28wk1.5 mge,c,g NCT04591626 · Phase 3 · registry result, not featured evidence · add on | 34.2% (n=366) vs 13.4% (n=365) Insulin Glargine @ 30wke,c,g NCT02058160 · Phase 3 · registry result, not featured evidence 2 other source trials43.2% (n=468) vs 25.1% (n=466) Insulin Glargine @ 30wk NCT02058147 · Phase 3 · registry result, not featured evidence 27.9% (n=233) vs 25.1% (n=466) Insulin Glargine @ 30wk NCT02058147 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7% responder rate · % of participants HbA1c <7.0% | 74.1% (n=239) vs 57.4% (n=242) Glimepiride @ 26wk1.5 mga,e,c NCT01644500 · Phase 3 · registry result, not featured evidence show 1 more dose63.6% (n=239) vs 57.4% (n=242) Glimepiride @ 26wk0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence | 42.1% (n=292) vs 38.4% (n=292) Insulin Glulisine @ 26wke,c HbA1c <7.0% NCT01768559 · Phase 3 · registry result, not featured evidence |
| HbA1c Less Than 7% responder rate · % of participants No placebo or comparator arm | 71.48% (n=526) @ 36wk4.5 mga,e,c,h NCT03495102 · Phase 3 show 2 more doses64.68% (n=521) @ 36wk3 mg NCT03495102 · Phase 3 56.98% (n=523) @ 36wk1.5 mg NCT03495102 · Phase 3 | 40.6% (n=239) @ 24wka,e,c,h NCT00712673 · Phase 3 · registry result, not featured evidence show 1 more dose43% (n=244) @ 24wk NCT00712673 · Phase 3 · registry result, not featured evidence |
| HOMA-B absolute change · percentage points | 37.03% (n=275) vs 35.59% (n=265) Liraglutide @ 26wk1.5 mg weeklye,c,i NCT01624259 · Phase 3 · registry result, not featured evidence | 6.72% (n=281) vs 6.98% (n=124) placebo @ 24wke,c,i NCT00763815 · Phase 3 · registry result, not featured evidence 2 other source trials17.66% (n=118) vs 17.79% (n=133) Sitagliptin @ 24wk NCT00976937 · Phase 3 · registry result, not featured evidence 4.83% (n=241) vs 6.63% (n=116) placebo @ 24wk NCT00713830 · Phase 3 · registry result, not featured evidence |
| UACR percent change · % of baseline | -7.23% (n=6482) vs -26.42% (n=6472) Tirzepatide @ 156wk1.5 mgb,c,j NCT04255433 · Phase 3 · registry result, not featured evidence | 24.17% (n=2803) vs 34.21% (n=2830) placebo @ 108wkb,c,j NCT01147250 · Phase 3 |
| Weight absolute change · kg No placebo or comparator arm | -0.5 kg @ 52wk1.5 mga,e,c,d NCT04809220 · Phase 3 · registry result, not featured evidence show 1 more dose-0.2 kg @ 52wk0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence | -2.8 kg @ 24wka,e,c,d NCT01517412 · Phase 3 · registry result, not featured evidence show 1 more dose-2.6 kg @ 24wk NCT01517412 · Phase 3 · registry result, not featured evidence |
| Dropout rate | 0.3%k NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 45 more results4.4% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 8.8%4.5 mg NCT03495102 · Phase 3 10.9%3 mg NCT03495102 · Phase 3 9.2%1.5 mg NCT03495102 · Phase 3 —1.5 mg NCT01621178 · Phase 3 —0.75 mg NCT01621178 · Phase 3 3.8%1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 3.9%0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —1.5 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence 2.5%Dulaglutide NCT02750410 · Phase 4 · registry result, not featured evidence — NCT03315780 · Phase 4 · registry result, not featured evidence 2.2%1.5 mg NCT04255433 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04809220 · Phase 3 · registry result, not featured evidence 3.1%0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04591626 · Phase 3 · registry result, not featured evidence · add on 4.9%1.5 mg NCT02597049 · Phase 3 · registry result, not featured evidence 3.5%0.75 mg NCT02597049 · Phase 3 · registry result, not featured evidence 8% NCT02152371 · Phase 3 · registry result, not featured evidence · combination 12.4%1.5 mg NCT01648582 · Phase 3 · registry result, not featured evidence 14.8%0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence 10.4% NCT01769378 · Phase 3 · registry result, not featured evidence 9%1.5 mg NCT01644500 · Phase 3 · registry result, not featured evidence 9.7%0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence —1.5 mg weekly NCT01624259 · Phase 3 · registry result, not featured evidence 10%LY2189265 NCT01624259 · Phase 3 · registry result, not featured evidence 9.2%4.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 5.1%3.0 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence — NCT01458210 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide + Warfarin NCT01432938 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide Alone NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy 16.7% NCT01436201 · Phase 1 · registry result, not featured evidence · combination | 32.5%l NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results9.2%Lixisenatide (One-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 8.3%Lixisenatide (Two-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 3.5% NCT01147250 · Phase 3 11.3% NCT05114590 · Phase 4 · registry result, not featured evidence 5.8% NCT05413369 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination NCT02787551 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination Whole Stud NCT02787551 · Phase 3 · registry result, not featured evidence 10.5%Insulin Glargine/Lixisenatide Fixe NCT02787551 · Phase 3 · registry result, not featured evidence 11.1% NCT02168491 · Phase 3 · registry result, not featured evidence · combination — NCT02058160 · Phase 3 · registry result, not featured evidence —Insulin Glargine/Lixisenatide Fixe NCT02058147 · Phase 3 · registry result, not featured evidence 12.4%Lixisenatide NCT02058147 · Phase 3 · registry result, not featured evidence 11.9% NCT01798706 · Phase 3 · registry result, not featured evidence 10.1% NCT01768559 · Phase 3 · registry result, not featured evidence 10.6%Lixisenatide Breakfast NCT01517412 · Phase 3 · registry result, not featured evidence 16%Lixisenatide Main Meal NCT01517412 · Phase 3 · registry result, not featured evidence 8.7% NCT01169779 · Phase 3 · registry result, not featured evidence 13% NCT00975286 · Phase 3 · registry result, not featured evidence 26% NCT00763815 · Phase 3 · registry result, not featured evidence 27.5%Lixisenatide (Evening Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 22.4%Lixisenatide (Morning Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 10.1% NCT00976937 · Phase 3 · registry result, not featured evidence 35.3% NCT00715624 · Phase 3 · registry result, not featured evidence 30.9% NCT00713830 · Phase 3 · registry result, not featured evidence 18.6%Lixisenatide (One-Step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 24.8%Lixisenatide (Two-step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence —Lixisenatide One-step Titration NCT00763451 · Phase 3 · registry result, not featured evidence 25%Lixisenatide (One-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 39.4%Lixisenatide (Two-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 13.6% NCT00866658 · Phase 3 · registry result, not featured evidence —20 µg NCT01596504 · Phase 2 · registry result, not featured evidence 4.2%20 μg NCT01596504 · Phase 2 · registry result, not featured evidence 6.8% NCT01476475 · Phase 2 · registry result, not featured evidence 2.6% NCT01175473 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —k NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 45 more results1.7% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.6%4.5 mg NCT03495102 · Phase 3 1.1%3 mg NCT03495102 · Phase 3 0.8%1.5 mg NCT03495102 · Phase 3 —1.5 mg NCT01621178 · Phase 3 —0.75 mg NCT01621178 · Phase 3 1.9%1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 —1.5 mg NCT02963766 · Phase 3 0%0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 —1.5 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT05659537 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence —0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence 1.7%Dulaglutide NCT02750410 · Phase 4 · registry result, not featured evidence — NCT03315780 · Phase 4 · registry result, not featured evidence —1.5 mg NCT04255433 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04809220 · Phase 3 · registry result, not featured evidence 0%0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence —1.5 mg NCT04591626 · Phase 3 · registry result, not featured evidence · add on 1.4%1.5 mg NCT02597049 · Phase 3 · registry result, not featured evidence 0%0.75 mg NCT02597049 · Phase 3 · registry result, not featured evidence 4% NCT02152371 · Phase 3 · registry result, not featured evidence · combination 2.3%1.5 mg NCT01648582 · Phase 3 · registry result, not featured evidence 4.3%0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence 4.2% NCT01769378 · Phase 3 · registry result, not featured evidence 2.5%1.5 mg NCT01644500 · Phase 3 · registry result, not featured evidence 0.4%0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence —1.5 mg weekly NCT01624259 · Phase 3 · registry result, not featured evidence 6%LY2189265 NCT01624259 · Phase 3 · registry result, not featured evidence 2.6%4.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 1.3%3.0 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence —0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence — NCT01458210 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide + Warfarin NCT01432938 · Phase 1 · registry result, not featured evidence · combination —Dulaglutide Alone NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy 8.3% NCT01436201 · Phase 1 · registry result, not featured evidence · combination | 14.1%l NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results2.5%Lixisenatide (One-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 4.2%Lixisenatide (Two-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 — NCT01147250 · Phase 3 0.8% NCT05114590 · Phase 4 · registry result, not featured evidence 0.3% NCT05413369 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination NCT02787551 · Phase 3 · registry result, not featured evidence —Fixed Ratio Combination Whole Stud NCT02787551 · Phase 3 · registry result, not featured evidence 3.9%Insulin Glargine/Lixisenatide Fixe NCT02787551 · Phase 3 · registry result, not featured evidence — NCT02168491 · Phase 3 · registry result, not featured evidence · combination — NCT02058160 · Phase 3 · registry result, not featured evidence —Insulin Glargine/Lixisenatide Fixe NCT02058147 · Phase 3 · registry result, not featured evidence 9%Lixisenatide NCT02058147 · Phase 3 · registry result, not featured evidence 8.5% NCT01798706 · Phase 3 · registry result, not featured evidence 5% NCT01768559 · Phase 3 · registry result, not featured evidence 4.9%Lixisenatide Breakfast NCT01517412 · Phase 3 · registry result, not featured evidence 4.4%Lixisenatide Main Meal NCT01517412 · Phase 3 · registry result, not featured evidence 5.6% NCT01169779 · Phase 3 · registry result, not featured evidence 8.5% NCT00975286 · Phase 3 · registry result, not featured evidence 9% NCT00763815 · Phase 3 · registry result, not featured evidence 10.2%Lixisenatide (Evening Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 8.2%Lixisenatide (Morning Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 2.5% NCT00976937 · Phase 3 · registry result, not featured evidence 11.2% NCT00715624 · Phase 3 · registry result, not featured evidence 12.4% NCT00713830 · Phase 3 · registry result, not featured evidence 8.7%Lixisenatide (One-Step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 11.8%Lixisenatide (Two-step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence —Lixisenatide One-step Titration NCT00763451 · Phase 3 · registry result, not featured evidence 13.9%Lixisenatide (One-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 21.2%Lixisenatide (Two-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 9.1% NCT00866658 · Phase 3 · registry result, not featured evidence —20 µg NCT01596504 · Phase 2 · registry result, not featured evidence 2.1%20 μg NCT01596504 · Phase 2 · registry result, not featured evidence 3.7% NCT01476475 · Phase 2 · registry result, not featured evidence 2.6% NCT01175473 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 40.3%k NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 45 more results5% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.2%4.5 mg NCT03495102 · Phase 3 7.3%3 mg NCT03495102 · Phase 3 8.7%1.5 mg NCT03495102 · Phase 3 21.4%1.5 mg NCT01621178 · Phase 3 25.3%0.75 mg NCT01621178 · Phase 3 —1.5 mg NCT02963766 · Phase 3 1.9%1.5 mg NCT02963766 · Phase 3 4%1.5 mg NCT02963766 · Phase 3 —0.75 mg NCT02963766 · Phase 3 2%0.75 mg NCT02963766 · Phase 3 2%0.75 mg NCT02963766 · Phase 3 0%1.5 mg NCT05659537 · Phase 4 · registry result, not featured evidence 0%0.75 mg NCT05659537 · Phase 4 · registry result, not featured evidence 2.5%0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence 5%0.75 mg NCT02750410 · Phase 4 · registry result, not featured evidence —Dulaglutide NCT02750410 · Phase 4 · registry result, not featured evidence 0% NCT03315780 · Phase 4 · registry result, not featured evidence 31.9%1.5 mg NCT04255433 · Phase 3 · registry result, not featured evidence 3.8%1.5 mg NCT04809220 · Phase 3 · registry result, not featured evidence 3.6%0.75 mg NCT04809220 · Phase 3 · registry result, not featured evidence 5.6%1.5 mg NCT04591626 · Phase 3 · registry result, not featured evidence · add on 3.5%1.5 mg NCT02597049 · Phase 3 · registry result, not featured evidence 2.1%0.75 mg NCT02597049 · Phase 3 · registry result, not featured evidence 6% NCT02152371 · Phase 3 · registry result, not featured evidence · combination 9.3%1.5 mg NCT01648582 · Phase 3 · registry result, not featured evidence 5.8%0.75 mg NCT01648582 · Phase 3 · registry result, not featured evidence 3.8% NCT01769378 · Phase 3 · registry result, not featured evidence 2.5%1.5 mg NCT01644500 · Phase 3 · registry result, not featured evidence 1.6%0.75 mg NCT01644500 · Phase 3 · registry result, not featured evidence 1.7%1.5 mg weekly NCT01624259 · Phase 3 · registry result, not featured evidence —LY2189265 NCT01624259 · Phase 3 · registry result, not featured evidence 3.9%4.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 8.9%3.0 mg NCT02973100 · Phase 2 · registry result, not featured evidence 3.7%1.5 mg NCT02973100 · Phase 2 · registry result, not featured evidence 0%1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%1.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%0.75 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0%0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 9.1%0.5 mg NCT01667900 · Phase 1 · registry result, not featured evidence 0% NCT01458210 · Phase 1 · registry result, not featured evidence · combination 0%Dulaglutide + Warfarin NCT01432938 · Phase 1 · registry result, not featured evidence · combination 0%Dulaglutide Alone NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy 0% NCT01436201 · Phase 1 · registry result, not featured evidence · combination | 8.2%l NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 34 more results0%Lixisenatide (One-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 0.8%Lixisenatide (Two-Step Titration) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 20.6% NCT01147250 · Phase 3 0.8% NCT05114590 · Phase 4 · registry result, not featured evidence 5.2% NCT05413369 · Phase 3 · registry result, not featured evidence 3.9%Fixed Ratio Combination NCT02787551 · Phase 3 · registry result, not featured evidence 10.2%Fixed Ratio Combination Whole Stud NCT02787551 · Phase 3 · registry result, not featured evidence —Insulin Glargine/Lixisenatide Fixe NCT02787551 · Phase 3 · registry result, not featured evidence 11.1% NCT02168491 · Phase 3 · registry result, not featured evidence · combination 5.5% NCT02058160 · Phase 3 · registry result, not featured evidence 3.8%Insulin Glargine/Lixisenatide Fixe NCT02058147 · Phase 3 · registry result, not featured evidence 3.9%Lixisenatide NCT02058147 · Phase 3 · registry result, not featured evidence 4.5% NCT01798706 · Phase 3 · registry result, not featured evidence 3.7% NCT01768559 · Phase 3 · registry result, not featured evidence 3.1%Lixisenatide Breakfast NCT01517412 · Phase 3 · registry result, not featured evidence 3.1%Lixisenatide Main Meal NCT01517412 · Phase 3 · registry result, not featured evidence 1.5% NCT01169779 · Phase 3 · registry result, not featured evidence 7.6% NCT00975286 · Phase 3 · registry result, not featured evidence 7.7% NCT00763815 · Phase 3 · registry result, not featured evidence 10.2%Lixisenatide (Evening Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 8.2%Lixisenatide (Morning Injection) NCT00712673 · Phase 3 · registry result, not featured evidence 1.9% NCT00976937 · Phase 3 · registry result, not featured evidence 14% NCT00715624 · Phase 3 · registry result, not featured evidence 10.1% NCT00713830 · Phase 3 · registry result, not featured evidence —Lixisenatide (One-Step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 13%Lixisenatide (Two-step Titration) NCT00763451 · Phase 3 · registry result, not featured evidence 9.9%Lixisenatide One-step Titration NCT00763451 · Phase 3 · registry result, not featured evidence 2.8%Lixisenatide (One-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 6.1%Lixisenatide (Two-step Titration) NCT00905255 · Phase 3 · registry result, not featured evidence 6.5% NCT00866658 · Phase 3 · registry result, not featured evidence 2.1%20 µg NCT01596504 · Phase 2 · registry result, not featured evidence —20 μg NCT01596504 · Phase 2 · registry result, not featured evidence 5.6% NCT01476475 · Phase 2 · registry result, not featured evidence 0% NCT01175473 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | k nausea 14.9% (placebo 5.4%) diarrhoea 13.5% (placebo 8.8%) nasopharyngitis 11.4% (placebo 10.8%) NCT01394952 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 41 more resultsnasopharyngitis 27.1% diarrhoea 12.2% nausea 9.4% NCT01584232 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.5 mg diarrhoea 21.2% (placebo 13.7%) headache 15.4% (placebo 9.8%) nausea 15.4% (placebo 7.8%) NCT02963766 · Phase 3 1.5 mg diarrhoea 12% (placebo 13.7%) nausea 12% (placebo 7.8%) abdominal pain upper 10% (placebo 7.8%) NCT02963766 · Phase 3 0.75 mg vomiting 17.6% (placebo 3.9%) diarrhoea 15.7% (placebo 13.7%) headache 13.7% (placebo 9.8%) NCT02963766 · Phase 3 0.75 mg headache 10.2% (placebo 9.8%) vomiting 8.2% (placebo 3.9%) abdominal pain 6.1% (placebo 5.9%) NCT02963766 · Phase 3 1.5 mg gastritis 14.3% dyslipidaemia 9.5% nausea 9.5% NCT05659537 · Phase 4 · registry result, not featured evidence 0.75 mg anaemia 21.4% gastritis 14.3% dyslipidaemia 7.1% NCT05659537 · Phase 4 · registry result, not featured evidence 0.75 mg nasopharyngitis 15.8% (placebo 30.8%) abdominal discomfort 8.3% (placebo 12.8%) constipation 6.7% (placebo 12.8%) NCT02750410 · Phase 4 · registry result, not featured evidence 0.75 mg nasopharyngitis 28.3% (placebo 30.8%) constipation 10.8% (placebo 12.8%) abdominal discomfort 9.2% (placebo 12.8%) NCT02750410 · Phase 4 · registry result, not featured evidence influenza 16.7% (placebo 0%) decreased appetite 8.3% (placebo 0%) diarrhoea 8.3% (placebo 8.3%) NCT03315780 · Phase 4 · registry result, not featured evidence 1.5 mg nausea 22.3% diarrhoea 18.9% covid-19 15.1% NCT04255433 · Phase 3 · registry result, not featured evidence 1.5 mg constipation 12.5% diarrhoea 10.2% pyrexia 10% NCT04809220 · Phase 3 · registry result, not featured evidence 0.75 mg constipation 8.7% nasopharyngitis 8.7% covid-19 8.2% NCT04809220 · Phase 3 · registry result, not featured evidence 1.5 mg decreased appetite 22.2% (placebo 4.1%) diabetic nephropathy 13.9% (placebo 15%) diarrhoea 13.2% (placebo 8.2%) NCT04591626 · Phase 3 · registry result, not featured evidence · add on 1.5 mg nausea 14.8% (placebo 3.6%) back pain 9.2% (placebo 7.1%) viral upper respiratory tract infection 6.3% (placebo 7.9%) NCT02597049 · Phase 3 · registry result, not featured evidence 0.75 mg diarrhoea 9.9% (placebo 2.9%) back pain 8.5% (placebo 7.1%) viral upper respiratory tract infection 5.7% (placebo 7.9%) NCT02597049 · Phase 3 · registry result, not featured evidence nausea 12% (placebo 1.3%) diarrhoea 11.3% (placebo 4%) upper respiratory tract infection 7.3% (placebo 6.7%) NCT02152371 · Phase 3 · registry result, not featured evidence · combination 1.5 mg hyperlipidaemia 17.8% diarrhoea 16.7% lipase increased 10.5% NCT01648582 · Phase 3 · registry result, not featured evidence 0.75 mg hyperlipidaemia 19.5% diarrhoea 10.9% hypertension 10.9% NCT01648582 · Phase 3 · registry result, not featured evidence nausea 10.5% (placebo 0%) diarrhoea 8.4% (placebo 0%) eructation 5.9% (placebo 0%) NCT01769378 · Phase 3 · registry result, not featured evidence 1.5 mg diarrhoea 17.2% hyperlipidaemia 11.1% nausea 10.2% NCT01644500 · Phase 3 · registry result, not featured evidence 0.75 mg hyperlipidaemia 12.1% diarrhoea 7.3% lipase increased 5.6% NCT01644500 · Phase 3 · registry result, not featured evidence 1.5 mg weekly nausea 20.4% diarrhoea 12% dyspepsia 8% NCT01624259 · Phase 3 · registry result, not featured evidence 4.5 mg nausea 30.3% (placebo 4.9%) diarrhoea 21.1% (placebo 11.1%) vomiting 13.2% (placebo 4.9%) NCT02973100 · Phase 2 · registry result, not featured evidence 3.0 mg nausea 25.3% (placebo 4.9%) diarrhoea 22.8% (placebo 11.1%) decreased appetite 16.5% (placebo 1.2%) NCT02973100 · Phase 2 · registry result, not featured evidence 1.5 mg nausea 22.2% (placebo 4.9%) diarrhoea 11.1% (placebo 11.1%) vomiting 11.1% (placebo 4.9%) NCT02973100 · Phase 2 · registry result, not featured evidence 1.5 mg decreased appetite 18.2% (placebo 0%) abdominal discomfort 9.1% (placebo 6.3%) blood pressure decreased 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 1.5 mg abdominal discomfort 10% (placebo 6.3%) decreased appetite 10% (placebo 0%) nausea 10% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.75 mg abdominal discomfort 9.1% (placebo 6.3%) nausea 9.1% (placebo 0%) vomiting 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.75 mg decreased appetite 18.2% (placebo 0%) abdominal discomfort 9.1% (placebo 6.3%) abdominal distension 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.5 mg abdominal discomfort 0% (placebo 6.3%) abdominal distension 0% (placebo 0%) abdominal pain 0% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence 0.5 mg decreased appetite 18.2% (placebo 0%) abdominal discomfort 9.1% (placebo 6.3%) abdominal pain 9.1% (placebo 0%) NCT01667900 · Phase 1 · registry result, not featured evidence headache 41.2% nausea 41.2% vomiting 35.3% NCT01458210 · Phase 1 · registry result, not featured evidence · combination diarrhoea 8% haemorrhoids 4% injection site pain 4% NCT01432938 · Phase 1 · registry result, not featured evidence · combination vomiting 11.5% decreased appetite 7.7% headache 7.7% NCT01432938 · Phase 1 · registry result, not featured evidence · monotherapy gastrooesophageal reflux disease 33.3% atrioventricular block first degree 28.6% headache 28.6% NCT01436201 · Phase 1 · registry result, not featured evidence · combination | l nausea 28.6% nasopharyngitis 15.4% diarrhoea 15.1% NCT00707031 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 31 more resultsnausea 20.2% (placebo 3.3%) headache 7.6% (placebo 8.2%) vomiting 6.7% (placebo 0%) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 nausea 24.2% (placebo 3.3%) headache 8.3% (placebo 8.2%) dizziness 7.5% (placebo 3.3%) NCT00688701 · Phase 3 · Type 2 Diabetes · phase 3 nausea 21.7% (placebo 5.9%) hypoglycaemia 20.1% (placebo 18.3%) dizziness 8.5% (placebo 6.3%) NCT01147250 · Phase 3 hypoglycaemia 5.7% upper respiratory tract infection 5.7% NCT05114590 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 17.2% covid-19 13.4% nausea 12.1% NCT05413369 · Phase 3 · registry result, not featured evidence nasopharyngitis 9.8% nausea 8.6% diarrhoea 5.5% NCT02787551 · Phase 3 · registry result, not featured evidence nasopharyngitis 15.5% nausea 9.2% diarrhoea 7.3% NCT02787551 · Phase 3 · registry result, not featured evidence mild asymptomatic hypoglycaemia 33.3% hypercholesterolaemia 22.2% mild gastrointestinal complaints 22.2% NCT02168491 · Phase 3 · registry result, not featured evidence · combination nausea 10.4% nasopharyngitis 8.8% headache 5.8% NCT02058160 · Phase 3 · registry result, not featured evidence nausea 9.6% diarrhoea 9% upper respiratory tract infection 7% NCT02058147 · Phase 3 · registry result, not featured evidence nausea 25% (placebo 7.5%) hypoglycaemia 17% (placebo 10.3%) diarrhoea 10.8% (placebo 7.5%) NCT01798706 · Phase 3 · registry result, not featured evidence hypoglycaemia 35.9% nausea 25.2% blood glucose decreased 20.1% NCT01768559 · Phase 3 · registry result, not featured evidence nausea 15.5% headache 7.1% nasopharyngitis 7.1% NCT01517412 · Phase 3 · registry result, not featured evidence nausea 14.7% nasopharyngitis 9.8% hypoglycaemia 6.7% NCT01517412 · Phase 3 · registry result, not featured evidence nausea 16.3% (placebo 2.6%) hypoglycaemia 9.2% (placebo 4.6%) dizziness 8.7% (placebo 4.1%) NCT01169779 · Phase 3 · registry result, not featured evidence hypoglycaemia 27.4% (placebo 19.3%) nausea 27.4% (placebo 4.9%) headache 9.9% (placebo 3.6%) NCT00975286 · Phase 3 · registry result, not featured evidence nausea 26% (placebo 13.7%) nasopharyngitis 16.4% (placebo 14.9%) headache 13.3% (placebo 11.8%) NCT00763815 · Phase 3 · registry result, not featured evidence nausea 24.7% (placebo 10.6%) headache 16.5% (placebo 23.5%) vomiting 15.7% (placebo 3.5%) NCT00712673 · Phase 3 · registry result, not featured evidence nausea 25.1% (placebo 10.6%) headache 19.2% (placebo 23.5%) diarrhoea 15.3% (placebo 11.8%) NCT00712673 · Phase 3 · registry result, not featured evidence nausea 17.7% headache 12.7% diarrhoea 8.9% NCT00976937 · Phase 3 · registry result, not featured evidence hypoglycaemia 42.1% (placebo 40.7%) nausea 29.3% (placebo 9.6%) headache 12.5% (placebo 10.2%) NCT00715624 · Phase 3 · registry result, not featured evidence nausea 28% (placebo 8.8%) hypoglycaemia 24.4% (placebo 19.3%) nasopharyngitis 15.9% (placebo 20.4%) NCT00713830 · Phase 3 · registry result, not featured evidence nausea 37.9% (placebo 8.1%) vomiting 18% (placebo 0.6%) diarrhoea 14.9% (placebo 13.1%) NCT00763451 · Phase 3 · registry result, not featured evidence nausea 29.2% (placebo 8.1%) vomiting 13% (placebo 0.6%) headache 12.4% (placebo 12.5%) NCT00763451 · Phase 3 · registry result, not featured evidence nausea 50% nasopharyngitis 36.1% decreased appetite 19.4% NCT00905255 · Phase 3 · registry result, not featured evidence nausea 36.4% nasopharyngitis 27.3% decreased appetite 18.2% NCT00905255 · Phase 3 · registry result, not featured evidence hypoglycaemia 43.5% (placebo 23.6%) nausea 39.6% (placebo 4.5%) vomiting 18.2% (placebo 1.9%) NCT00866658 · Phase 3 · registry result, not featured evidence 20 µg decreased appetite 18.8% nausea 18.8% nasopharyngitis 12.5% NCT01596504 · Phase 2 · registry result, not featured evidence nausea 7.5% nasopharyngitis 5.6% headache 5% NCT01476475 · Phase 2 · registry result, not featured evidence nausea 22.1% decreased appetite 18.2% headache 11.7% NCT01175473 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 52 weeks versus 24 weeks.
- ePopulation comparability has not been reviewed for both studies.
- fAssessment timepoints differ: 26 weeks versus 30 weeks.
- gAssessment timepoints differ: 28 weeks versus 30 weeks.
- hAssessment timepoints differ: 36 weeks versus 24 weeks.
- iAssessment timepoints differ: 26 weeks versus 24 weeks.
- jAssessment timepoints differ: 156 weeks versus 108 weeks.
- kPopulation comparability has not been reviewed for 44 of these studies.
- lPopulation comparability has not been reviewed for 32 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
dulaglutide
show 1 more result
show 4 more results
show 3 more results
show 1 more result
show 2 more results
show 3 more results
+ 49 further endpoints in the CSV export.
lixisenatide
show 9 more results
show 8 more results
show 1 more result
show 6 more results
show 3 more results
show 3 more results
+ 57 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: dulaglutide's landscape · lixisenatide's landscape